FDA set to review Sandoz's generic GLP-1s - Reuters
FDA set to review Sandoz's generic GLP-1s Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxNLVlzR3pucWtYRUVfanZpRGJKekFndFNKTUJPQWZYMnpTR3dIYWcyc2g3SUpzR1ROcHdrZnFuZmZ2NWQyQXVzWUhHUjdwcEhWdldrd2JyMkNkQjNjbkYyQ2x5WVRaM1JCLUw1dEUzaU5lVk1FaVFkRTk2MW5KdjROTFA1V09HbjBzXzVqSWZScGowQk8yTUpnWW5GSG10T1BCQ21famxKQXFBaEZjYVE?oc=5" target="_blank">FDA set to review Sandoz's generic GLP-1s</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data - Reuters
Capricor shares skyrocket as FDA agrees to review new Duchenne drug data Reuters
August 14, 2026 at 10:41 AMUS FDA approves Regeneron's rare bone disorder drug - Reuters
US FDA approves Regeneron's rare bone disorder drug Reuters
August 19, 2026 at 06:53 PMNovo begins study to find lowest effective dose for Wegovy pill - Reuters
Novo begins study to find lowest effective dose for Wegovy pill Reuters
August 19, 2026 at 03:26 PMUS FDA approves Bristol Myers' blood cancer treatment - Reuters
US FDA approves Bristol Myers' blood cancer treatment Reuters
August 13, 2026 at 09:33 PMLilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide - reuters.com
Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide reuters.com
August 12, 2026 at 10:27 AMNovartis defeats UK court bid to invalidate blockbuster drug Entresto patent - Reuters
Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent Reuters
August 13, 2026 at 09:31 PM